Real-world study of carrelizumab in the treatment of malignant tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032979

Enrollment

Unknown

Registered

2020-05-17

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

single arm:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. According to the instructions, relevant guidelines, clinical diagnosis and treatment routines, and their own clinical experience, the clinician believes that the application of carrelizumab may benefit; 2. Patients who are >= 18 years old and have no gender limit, but voluntarily join the study and sign informed consent; 3. Malignant solid tumors confirmed by histopathology or cytopathology.

Exclusion criteria

Exclusion criteria: Null

Design outcomes

Primary

Measure	Time frame
PFS;AEs;	—

Secondary

Measure	Time frame
OS;SAEs;ORR;DCR;	—

Countries

China

Contacts

Public ContactBu Qing

The First Affiliated Hospital of Guangxi Medical University

549623730@qq.com+86 13490209812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026